Acrivon Therapeutics (ACRV) Expected to Announce Quarterly Earnings on Wednesday

Acrivon Therapeutics (NASDAQ:ACRV) is expected to be announcing its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.57) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Friday, November 21, 2025 at 4:00 PM ET.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its earnings results on Wednesday, August 13th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.02. On average, analysts expect Acrivon Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Acrivon Therapeutics Trading Down 6.0%

NASDAQ ACRV opened at $1.88 on Monday. The firm’s 50 day simple moving average is $1.78 and its 200 day simple moving average is $1.46. The firm has a market capitalization of $59.14 million, a price-to-earnings ratio of -0.84 and a beta of 1.82. Acrivon Therapeutics has a 1 year low of $1.05 and a 1 year high of $8.66.

Hedge Funds Weigh In On Acrivon Therapeutics

Large investors have recently bought and sold shares of the company. Invesco Ltd. bought a new stake in shares of Acrivon Therapeutics during the first quarter worth about $72,000. XTX Topco Ltd bought a new position in Acrivon Therapeutics in the 2nd quarter valued at approximately $126,000. Finally, Jane Street Group LLC acquired a new stake in Acrivon Therapeutics during the 2nd quarter worth approximately $371,000. 71.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acrivon Therapeutics in a research note on Wednesday, October 8th. Oppenheimer reduced their price objective on Acrivon Therapeutics from $9.00 to $8.00 and set an “outperform” rating on the stock in a research note on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Acrivon Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.